New Rhein Healthcare Investors
Greg Parekh currently serves as the CEO and Chairman of the Board at Alveus Therapeutics, and holds the position of Chairman of the Board of Directors at Butterfly Medical. Additionally, Parekh is a Member of the Board of Directors at American Injectables and is the Founder and Managing Partner of New Rhein Healthcare Investors, a venture capital firm comprised of former pharmaceutical industry executives. Parekh's previous roles include Chairman of the Board at Chase Pharmaceuticals and CEO of Biocartis, where significant capital was raised and strategic growth was directed into Oncology. Parekh has also been involved with Novartis as Head of M&A and has a robust background in investment banking from Deutsche Bank. Academic credentials include a PhD in Economics from Northwestern University and a BA in Economics and Political Science from the University of Rochester.
This person is not in any teams
This person is not in any offices
New Rhein Healthcare Investors
New Rhein is a Venture Capital/ Private Equity investor. Its partners are former pharmaceutical industry executives having both operational and M&A experience. New Rhein invests in healthcare companies with the objective of helping management teams build their business into a profile strategic investors would find attractive. We use our knowledge of what strategic buyers want and our relationships to help our portfolio companies achieve this goal. Investment areas of focus include specialty Rx (eg hospital), branded and difficult to make Gx, OTC, biologics, vaccines, and emerging markets (in particular China and Brazil). We are interested in product only deals, carve-outs and entire company purchases.